36.26 +1.54(4.44%) Date:

Credit Suisse Initiates Sarepta Therapeutics Inc (SRPT) With Outperform; Shares Shoot Up

Credit Suisse analysts believe Exondys 51 may only be the beginning for Sarepta

Sarepta Therapeutics Inc (SRPT): Wedbush Expects Rapid Uptake Of DMD Drug On Launch

Wedbush analyst believes Exondys 51 will not face concerning reimbursement challenges